Abstract: The present application provides modified immune cells that express TLR receptors. In some embodiments, the modified immune cell further comprises an engineered receptor such as a chimeric antigen receptor (CAR). The present application also provides methods and pharmaceutical compositions for cancer treatment using the modified immune cells described herein.

Abstract: An immune effector cell expressing a chimeric cytokine receptor comprising a first extracellular antigen binding domain, a first transmembrane domain, and a cytokine receptor intracellular domain; and a functional exogenous receptor comprising a second extracellular antigen binding domain, a second transmembrane domain, and an intracellular signaling domain.

Abstract: The present disclosure relates to a novel platform for immunotherapy which combines CAR or TCR engineered ?? T cells with armoring interleukin IL-36 that can be expressed constitutively or inducibly, or with a chimeric cytokine receptor comprising the endodomain of the IL-36 receptor. The system/platform and the associated methods according to the present disclosure have advantages such as increased immune cell potency and persistence for therapeutic applications.